Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma
Cancers · 10.04.2024 · 16 (8) · 1453
DOI: 10.3390/cancers16081453 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.04.2024. Verfasst von Sami Fares und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Pancreato-Biliary & Liver Transplant Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, …. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepato-Pancreato-Biliary & Liver Transplant Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
- Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
- Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
ORCID-Profile: Chase J Wehrle, Chunbao Jiao, Mingyi Zhang, Abby Gross, Suneel Kamath, Alejandro Pita
Zitieren
APA
Fares, S., Wehrle, C. J., Hong, H., Sun, K., Jiao, C., Zhang, M., Gross, A., Allkushi, E., Uysal, M., Kamath, S., Ma, W. W., Modaresi Esfeh, J., Linganna, M. W., Khalil, M., Pita, A., Kim, J., Walsh, R. M., Miller, C., Hashimoto, K., …, & Aucejo, F. (2024). Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma. Cancers, 16(8), 1453. https://doi.org/10.3390/cancers16081453
Vancouver
Fares S, Wehrle CJ, Hong H, Sun K, Jiao C, Zhang M, et al. Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma. Cancers. 2024;16(8):1453. doi:10.3390/cancers16081453
BibTeX
@article{Fares2024,
author = {Fares, Sami and Wehrle, Chase J and Hong, Hanna and Sun, Keyue and Jiao, Chunbao and Zhang, Mingyi and Gross, Abby and Allkushi, Erlind and Uysal, Melis and Kamath, Suneel and Ma, Wen Wee and Modaresi Esfeh, Jamak and Linganna, Maureen Whitsett and Khalil, Mazhar and Pita, Alejandro and Kim, Jaekeun and Walsh, R Matthew and Miller, Charles and Hashimoto, Koji and Schlegel, Andrea and Kwon, David Choon Hyuck and Aucejo, Federico},
title = {Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {8},
pages = {1453},
doi = {10.3390/cancers16081453}
}
EUVIMED